Every 8-K that Protagonist Ther (PTGX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PTGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTGX filings page.
Protagonist Therapeutics reported a strong turnaround for the quarter ended June 30, 2026, driven by collaboration economics. License and collaboration revenue reached approximately $213.5 million, mainly from recognizing $192.4 million of a $200 million opt-out payment from Takeda and development services, plus earlier in 2026 a $50 million milestone from Johnson & Johnson tied to ICOTYDE’s FDA approval. Net income was about $162.8 million, compared with a loss a year earlier; diluted earnings per share were $2.29.
Cash, cash equivalents and marketable securities totaled roughly $849.5 million as of June 30, 2026, with stockholders’ equity of $841.5 million. ICOTYDE had its first full quarter of commercial sales, while rusfertide’s NDA for polycythemia vera is under FDA priority review with a PDUFA date in August 2026. The company highlighted a broad partnered and wholly owned pipeline, including the oral IL-17 antagonist PN-881 and triple agonist obesity candidate PN-477, and emphasized that expected milestones and tiered royalties of 6–10% on ICOTYDE and 14–29% on rusfertide are intended to fund ongoing R&D with no anticipated near-term equity financing.
Protagonist Therapeutics, Inc. held its 2026 annual stockholder meeting, with 64,305,185 common shares entitled to vote. Stockholders approved a new 2026 Equity Incentive Plan, which replaces the 2016 plan and allows future awards using remaining 2016 plan shares plus 650,000 new shares and certain returning shares.
Two Class I directors, Dinesh V. Patel and Lewis T. “Rusty” Williams, were re-elected to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, executive compensation and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Protagonist Therapeutics posted a profitable first quarter of 2026 while securing major regulatory and partnership milestones. License and collaboration revenue reached $56.4 million, up from $28.3 million a year earlier, driving net income of $3.8 million versus a prior-period net loss of $11.7 million.
ICOTYDE received U.S. FDA approval for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment and positioning Protagonist to earn up to $580 million more in milestones plus 6%–10% tiered royalties. Rusfertide’s NDA was accepted with Priority Review and a PDUFA goal date in August 2026.
By opting out of the U.S. profit and loss sharing with Takeda for rusfertide, Protagonist unlocked a $200 million payment, with eligibility for an additional $200 million opt-out fee, a $75 million approval milestone, and up to $775 million in sales milestones, alongside 14%–29% worldwide royalties. Cash, cash equivalents and marketable securities totaled $620 million as of March 31, 2026, which the company expects to fund operations through at least 2028.
Protagonist Therapeutics reported a challenging 2025 financially but highlighted major regulatory and pipeline milestones. License and collaboration revenue fell to $46.0 million from $434.4 million in 2024, while research and development expense rose to $159.3 million and general and administrative expense to $44.9 million.
The company posted a full-year net loss of $130.1 million, or $2.05 per basic and diluted share, compared with net income of $275.2 million in 2024. In the fourth quarter, net loss was $44.4 million, versus net income of $131.7 million a year earlier.
Strategically, Protagonist submitted an NDA for rusfertide in December 2025 and has an NDA for ICOTYDE™ under FDA review, with a U.S. regulatory decision for ICOTYDE anticipated in 2026. The company expects to opt out of the 50:50 U.S. profit and loss sharing for rusfertide with Takeda during a 90‑day window expected to open in Q2 2026.
Protagonist ended 2025 with cash, cash equivalents and marketable securities of $646.0 million, up from $559.2 million, which it believes will fund operations through at least the end of 2028. The pipeline includes PN‑881, with Phase 1 completion expected by mid‑2026, and several wholly owned preclinical obesity and hepcidin‑focused candidates.
Protagonist Therapeutics, Inc. reported that it has made an updated corporate presentation available as of January 12, 2026. The presentation is provided as Exhibit 99.1 to a current report on Form 8-K under Regulation FD, which is intended to share information broadly with the market. The company notes that this information, including the exhibit, is being furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other SEC filings.
Protagonist Therapeutics (PTGX) filed a current report announcing it has reported financial results for the quarter ended September 30, 2025. The company furnished a press release titled “Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update” as Exhibit 99.1.
The report states the information, including the exhibit, is furnished and not deemed “filed” under the Exchange Act and will not be incorporated by reference into other SEC filings. The filing lists PTGX common stock on The Nasdaq Stock Market and is signed by Chief Financial Officer Asif Ali.
Protagonist Therapeutics (NASDAQ:PTGX) filed an 8-K reporting the final voting results of its 2025 Annual Meeting held on June 20, 2025.
- Directors elected: Harold E. Selick, Ph.D. (44.8 M for / 9.2 M withheld) and Bryan Giraudo (42.5 M for / 11.5 M withheld) to serve until 2028.
- Say-on-Pay: Executive compensation approved with 50.8 M votes for (92.6% of votes cast).
- Auditor ratification: Ernst & Young LLP confirmed with 55.5 M votes for (99.1%).
No other matters were brought before shareholders, and the meeting produced routine outcomes with no material corporate changes.